文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

单倍型结构定义常见DPYD变异c.85T>C和c.496A>G对二氢嘧啶脱氢酶活性的影响:对5-氟尿嘧啶毒性的意义

Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity.
PubMed 文献 · Br J Clin Pharmacol · 2021-03-30

该研究在4项独立研究的1382名受试者中测量血浆二氢尿嘧啶/尿嘧啶比值作为DPD活性标志,评估基因型和单倍型与比值的关系。发现DPYD c.496A>G与比值降低相关,是5-FU毒性的强候选风险等位基因;c.85T>C可能具有保护作用,但连锁等位基因的限制可能削弱该效应。

要点

  • DPYD c.496A>G与UH2/U比值降低12.6%相关,是5-FU毒性强候选风险等位基因。
  • 携带c.496A>G的单倍型H3和H5均与比值降低相关(MD分别为-9.6%和-16.9%)。
  • 仅携带c.85T>C的单倍型H2与比值升高相关(MD +8.6%),可能具有保护作用。

核心结论

  • DPYD c.496A>G是5-FU毒性的强候选风险等位基因。
  • DPYD c.85T>C可能具有保护作用,但与c.496A>G和c.1129-5923C>G的连锁不平衡可能限制该效应。

研究设计与样本

  • 在4项独立研究共1382名受试者中测量血浆二氢尿嘧啶/尿嘧啶比值作为DPD活性群体标志。
  • 评估基因型和单倍型与UH2/U比值的相关性。

主要发现

  • 携带4个已知5-FU毒性风险变异者UH2/U比值显著降低(P<2×10^-16):c.1905+1G>A(rs3918290)平均差异-43.7%,c.1679T>G(rs55886062)-46.0%,c.2846A>T(rs67376798)-37.1%,c.1129-5923C>G(rs75017182)-13.2%。
  • DPYD c.496A>G(rs2297595)与UH2/U比值降低相关(P<.0001,平均差异-12.6%)。
  • 携带c.496A>G的单倍型H3与比值降低相关(P=.003,平均差异-9.6%),H5与比值降低相关(P=.002,平均差异-16.9%)。
  • 仅携带c.85T>C的单倍型H2与比值升高相关(P=.004,平均差异+8.6%)。

局限性

  • c.85T>C可能的保护效应及与c.496A>G和c.1129-5923C>G的连锁不平衡可能干扰了既往关联研究,未来临床研究应考虑此因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to identify risk variants and haplotypes that impair dihydropyrimidine dehydrogenase (DPD) activity and are, therefore, candidate risk variants for severe toxicity to 5-fluorouracil (5-FU) chemotherapy. METHODS: Plasma dihydrouracil/uracil (UH2 /U) ratios were measured as a population marker for DPD activity in a total of 1382 subjects from 4 independent studies. Genotype and haplotype correlations with UH2 /U ratios were assessed. RESULTS: Significantly lower UH2 /U ratios (panova < 2 × 10-16 ) were observed in carriers of the 4 well-studied 5-FU toxicity risk variants with mean differences (MD) of -43.7% for DPYD c.1905 + 1G > A (rs3918290), -46.0% for DPYD c.1679T > G (rs55886062), -37.1%, for DPYD c.2846A > T (rs67376798), and -13.2% for DPYD c.1129-5923C > G (rs75017182). An additional variant, DPYD c.496A > G (rs2297595), was also associated with lower UH2 /U ratios (P < .0001, MD: -12.6%). A haplotype analysis was performed for variants in linkage disequilibrium with c.496A > G, which consisted of the common variant c.85T > C (rs1801265) and the risk variant c.1129-5923C > G. Both haplotypes carrying c.496A > G were associated with decreased UH2 /U ratios (H3, P = .003, MD: -9.6%; H5, P = .002, MD: -16.9%). A haplotype carrying only the variant c.85T > C (H2) was associated with elevated ratios (P = .004, MD: +8.6%). CONCLUSIONS: Based on our data, DPYD-c.496A > G is a strong candidate risk allele for 5-FU toxicity. Our data suggest that DPYD-c.85T > C might be protective; however, the deleterious impacts of the linked alleles c.496A > G and c.1129-5923C > G likely limit this effect in patients. The possible protective effect of c.85T > C and linkage disequilibrium with c.496A > G and c.1129-5923C > G may have hampered prior association studies and should be considered in future clinical studies.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Hamzic S, Schärer D, Offer SM, et al. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity. Br J Clin Pharmacol. 2021. PMID: 33491253. doi:10.1111/bcp.14742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。